Mitsubishi UFJ Trust & Banking Corp Sells 37,100 Shares of Guardant Health, Inc. (NASDAQ:GH)

Mitsubishi UFJ Trust & Banking Corp cut its holdings in Guardant Health, Inc. (NASDAQ:GH) by 11.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 292,972 shares of the company’s stock after selling 37,100 shares during the period. Mitsubishi UFJ Trust & Banking Corp owned 0.24% of Guardant Health worth $8,950,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in GH. Intech Investment Management LLC bought a new position in Guardant Health during the third quarter worth $754,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Guardant Health by 6.8% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 28,986 shares of the company’s stock valued at $665,000 after buying an additional 1,844 shares during the last quarter. Verition Fund Management LLC lifted its stake in shares of Guardant Health by 220.6% in the third quarter. Verition Fund Management LLC now owns 37,641 shares of the company’s stock valued at $863,000 after buying an additional 25,900 shares during the period. PDT Partners LLC grew its position in Guardant Health by 51.8% during the third quarter. PDT Partners LLC now owns 219,542 shares of the company’s stock worth $5,036,000 after buying an additional 74,957 shares in the last quarter. Finally, Erste Asset Management GmbH bought a new position in Guardant Health during the third quarter valued at about $21,389,000. 92.60% of the stock is currently owned by institutional investors.

Guardant Health Stock Down 4.5 %

Shares of NASDAQ GH opened at $43.14 on Friday. The company has a market cap of $5.32 billion, a price-to-earnings ratio of -12.12 and a beta of 1.50. Guardant Health, Inc. has a 12-month low of $15.81 and a 12-month high of $50.89. The firm’s 50-day simple moving average is $44.66 and its 200 day simple moving average is $34.30.

Guardant Health (NASDAQ:GH) last released its quarterly earnings results on Thursday, February 20th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.15). Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The company had revenue of $201.81 million for the quarter, compared to the consensus estimate of $192.50 million. On average, equities analysts expect that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. Morgan Stanley lifted their price objective on Guardant Health from $42.00 to $52.00 and gave the stock an “overweight” rating in a report on Thursday, March 6th. Stifel Nicolaus lifted their price target on shares of Guardant Health from $45.00 to $53.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. Piper Sandler raised their price objective on shares of Guardant Health from $34.00 to $50.00 and gave the stock an “overweight” rating in a report on Wednesday, February 26th. Canaccord Genuity Group upped their target price on shares of Guardant Health from $42.00 to $60.00 and gave the company a “buy” rating in a research note on Monday, February 24th. Finally, Barclays initiated coverage on shares of Guardant Health in a research report on Thursday, January 23rd. They issued an “overweight” rating and a $60.00 price target for the company. Twenty investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $48.95.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.